Totaling the number of both nonsynonymous and synonymous mutations, the calculated HSA mutation burden is estimated to be 0.1–2.1 mutations per megabase, which falls on the low end of the mutation burden observed in human tumors (ranging 0.001–400 mutations per megabase), and is comparable to human tumors with low mutational burdens such as ovarian cancer and sarcomas [11,12]. This evidence concerns the gene ALB and ovarian carcinoma.